| Basics |
Cyclacel Pharmaceuticals, Inc.
Cyclacel Pharmaceuticals Inc mainly develops targeted medicines for cancer and other proliferative diseases. The company focuses in hematology and oncology-based development pipeline of novel drug candidates.
|
| IPO Date: |
April 1, 2004 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$38.49M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.11 | 4.20%
|
| Avg Daily Range (30 D): |
$0.13 | 10.33%
|
| Avg Daily Range (90 D): |
$0.06 | 6.83%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.41M |
| Avg Daily Volume (30 D): |
3.79M |
| Avg Daily Volume (90 D): |
1.46M |
| Trade Size |
| Avg Trade Size (Sh.): |
408 |
| Avg Trade Size (Sh.) (30 D): |
640 |
| Avg Trade Size (Sh.) (90 D): |
644 |
| Institutional Trades |
| Total Inst.Trades: |
38 |
| Avg Inst. Trade: |
$1.11M |
| Avg Inst. Trade (30 D): |
$M |
| Avg Inst. Trade (90 D): |
$M |
| Avg Inst. Trade Volume: |
M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$1.48M |
| Avg Closing Trade (30 D): |
$M |
| Avg Closing Trade (90 D): |
$M |
| Avg Closing Volume: |
.75K |
|
|
|
|
| Financials |
| |
TTM |
Q1 2025 |
Q4 2024 |
|
Basic EPS
|
$.18
|
$
|
|
|
Diluted EPS
|
$.18
|
$
|
|
|
Revenue
|
$ .01M
|
$ M
|
$ M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -8.35M
|
$ -.08M
|
$ -3.05M
|
|
Operating Income / Loss
|
$ -12.69M
|
$ -5.04M
|
$ -1.83M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ M
|
$ M
|
$ M
|
|
PE Ratio
|
9.00
|
|
|
| Splits |
|
Dec 18, 2023:
1:225
|
|
Apr 15, 2020:
1:20
|
|
May 31, 2016:
1:12
|
|
Aug 27, 2012:
1:7
|
|
